Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Trial ID or NCT#

NCT00637923

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in treatment-naive patients.

Official Title

Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Chronic hepatitis C genotype 1.
Exclusion Criteria:
  1. - Patients that have previously received treatment with any interferon or interferon-based treatment for chronic hepatitis C. - Females of child-bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active. - Males whose female partners are either pregnant or of child-bearing potential or not using birth control and are sexually active. - Other causes of liver disease including autoimmune hepatitis. - Transplant recipients receiving immune suppression therapy. - Screening tests positive for Anti-Hepatitis A Virus Immunoglobulin M Antibody (anti-HAV IgM Ab), Hepatitis B's antigen (HBsAg), Anti-Hepatitis B core Immunoglobulin M Antibody (anti-HBc IgM Ab) or Anti-Human Immunodeficiency Virus Antibody (anti-HIV Ab). - Decompensated cirrhosis, history of variceal bleeding, ascites, hepatic encephalopathy, Child-Turcotte-Pugh (CTP) score >6 or Model for End-stage Liver Disease (MELD) score >8. - Alcohol consumption of >40 grams per day or an alcohol use pattern that will interfere with the study. - Absolute neutrophil count <1500 cells/mm3; platelet count <135,000 cells/mm3; hemoglobin <12 g/dL for women and <13 g/dL for men; or serum creatinine concentration ≥1.5 times Upper Limit of Normal (ULN). - Hypothyroidism or hyperthyroidism not effectively treated with medication. - Hemoglobin A1C (HgbA1c) >7.5 or history of diabetes mellitus. - Body Mass Index (BMI) >34. - History or other clinical evidence of significant or unstable cardiac disease. - History or other clinical evidence of chronic pulmonary disease associated with functional impairment. - Serious or severe bacterial infection(s). - Ulcerative or hemorrhagic/ischemic colitis. - Pancreatitis. - History of severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization. - History of uncontrolled severe seizure disorder. - Requires concomitant theophylline or methadone. - History of immunologically mediated disease requiring more than intermittent anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids. - History or other evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension. - Hemoglobinopathies. - History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectable solution or ribavirin tablets.

Investigator(s)

Ramsey Cheung

Contact us to find out if this trial is right for you.

Contact

Shawna Thunen
6507235512